Trial · NCT01352793
Results by group60
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 60
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With at Least One Serious Adverse Event (SAE) Throughout the Study | Group 1: rLP2086 | 1.55 | 95% Confidence Interval 1.2 to 2.0 | percentage of participants | |
| Percentage of Participants With at Least One Serious Adverse Event (SAE) Throughout the Study | Group 2: HAV/Saline/HAV | 2.52 | 95% Confidence Interval 1.9 to 3.3 | percentage of participants | |
| Percentage of Participants With at Least One Medically Attended Adverse Event Within 30 Days After Vaccination 1 | Group 1: rLP2086 | 7.03 | 95% Confidence Interval 6.2 to 7.9 | percentage of participants | |
| Percentage of Participants With at Least One Medically Attended Adverse Event Within 30 Days After Vaccination 1 | Group 2: HAV/Saline/HAV | 6.13 | 95% Confidence Interval 5.1 to 7.3 | percentage of participants | |
| Percentage of Participants With at Least One Medically Attended Adverse Event Within 30 Days After Vaccination 2 | Group 1: rLP2086 | 5.50 | 95% Confidence Interval 4.8 to 6.3 | percentage of participants | |
| Percentage of Participants With at Least One Medically Attended Adverse Event Within 30 Days After Vaccination 2 | Group 2: HAV/Saline/HAV | 6.09 | 95% Confidence Interval 5.0 to 7.3 | percentage of participants | |
| Percentage of Participants With at Least One Medically Attended Adverse Event Within 30 Days After Vaccination 3 | Group 1: rLP2086 | 5.34 | 95% Confidence Interval 4.6 to 6.2 | percentage of participants | |
| Percentage of Participants With at Least One Medically Attended Adverse Event Within 30 Days After Vaccination 3 | Group 2: HAV/Saline/HAV | 5.50 | 95% Confidence Interval 4.50 to 6.7 | percentage of participants | |
| Percentage of Participants With at Least One Serious Adverse Event (SAE) During Pre-specified Time Periods | Group 1: rLP2086 | 30 days after Vaccination 1 (N=3796, 1908) | 0.18 | 95% Confidence Interval 0.1 to 0.4 | percentage of participants |
| Percentage of Participants With at Least One Serious Adverse Event (SAE) During Pre-specified Time Periods | Group 2: HAV/Saline/HAV | 30 days after Vaccination 1 (N=3796, 1908) | 0.42 | 95% Confidence Interval 0.2 to 0.8 | percentage of participants |
| Percentage of Participants With at Least One Serious Adverse Event (SAE) During Pre-specified Time Periods | Group 1: rLP2086 | 30 days after Vaccination 2 (N=3529, 1806) | 0.17 | 95% Confidence Interval 0.1 to 0.4 | percentage of participants |
| Percentage of Participants With at Least One Serious Adverse Event (SAE) During Pre-specified Time Periods | Group 2: HAV/Saline/HAV | 30 days after Vaccination 2 (N=3529, 1806) | 0.44 | 95% Confidence Interval 0.2 to 0.9 | percentage of participants |
| Percentage of Participants With at Least One Serious Adverse Event (SAE) During Pre-specified Time Periods | Group 1: rLP2086 | 30 days after Vaccination 3 (N=3313, 1710) | 0.33 | 95% Confidence Interval 0.2 to 0.6 | percentage of participants |
| Percentage of Participants With at Least One Serious Adverse Event (SAE) During Pre-specified Time Periods | Group 2: HAV/Saline/HAV | 30 days after Vaccination 3 (N=3313, 1710) | 0.12 | 95% Confidence Interval 0.0 to 0.4 | percentage of participants |
| Percentage of Participants With at Least One Serious Adverse Event (SAE) During Pre-specified Time Periods | Group 1: rLP2086 | 30 days after any vaccination (N=3796, 1908) | 0.61 | 95% Confidence Interval 0.4 to 0.9 | percentage of participants |
| Percentage of Participants With at Least One Serious Adverse Event (SAE) During Pre-specified Time Periods | Group 2: HAV/Saline/HAV | 30 days after any vaccination (N=3796, 1908) | 0.94 | 95% Confidence Interval 0.6 to 1.5 | percentage of participants |
| Percentage of Participants With at Least One Serious Adverse Event (SAE) During Pre-specified Time Periods | Group 1: rLP2086 | Vaccination phase (N=3796, 1908) | 1.16 | 95% Confidence Interval 0.8 to 1.6 | percentage of participants |
| Percentage of Participants With at Least One Serious Adverse Event (SAE) During Pre-specified Time Periods | Group 2: HAV/Saline/HAV | Vaccination phase (N=3796, 1908) | 1.83 | 95% Confidence Interval 1.3 to 2.5 | percentage of participants |
| Percentage of Participants With at Least One Serious Adverse Event (SAE) During Pre-specified Time Periods | Group 1: rLP2086 | Follow-up phase (N=3400, 1733) | 0.44 | 95% Confidence Interval 0.2 to 0.7 | percentage of participants |
| Percentage of Participants With at Least One Serious Adverse Event (SAE) During Pre-specified Time Periods | Group 2: HAV/Saline/HAV | Follow-up phase (N=3400, 1733) | 0.87 | 95% Confidence Interval 0.5 to 1.4 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01352793/results